Lisa A. Carey, MD, of the University of North Carolina, and Jay Harris, MD, of Dana-Farber Cancer Institute and Brigham and Women’s Hospital, discuss Dr. Harris' plenary lecture.
Clifford A. Hudis, MD, of Memorial Sloan Kettering Cancer Center, and William J. Gradishar, MD, of the Lurie Comprehensive Cancer Center, discuss the most important papers and results at this year's San Antonio Breast Cancer Symposium.
Harold J. Burstein, MD, PhD, of the Dana-Farber Cancer Institute, discusses the CREATE-X adjuvant study of capecitabine in high-risk patients with residual disease (Abstract S6-01).
William M. Sikov, MD, of Women and Infants Hospital of Rhode Island, discusses the results of this study that showed pathologic complete response to presurgery chemotherapy improved survival (Abstract S2-05).
Michael Gnant, MD, of the Medical University of Vienna, discusses a study in which denosumab was added to adjuvant aromatase inhibitor therapy to improve disease-free survival in postmenopausal patients with early-stage, hormone receptor–positive breast cancer (Abstract S2-02).
Sarat Chandarlapaty, MD, PhD, of the Memorial Sloan Kettering Cancer Center, discusses results from this study that showed patients with ER-positive metastatic breast cancer who had a D538G and/or a Y537S mutation in the ESR1 gene had significantly worse median overall survival (Abstract S2-07).
